Form 8-K · Current report
Dexcom 8-K, filed Sep 10, 2026
- Filed
- CIK
- 0001093557
- Accession no.
- 0001093557-26-000167
Summary
DexCom, Inc. appointed Glenn S. Boehnlein to its board of directors effective September 10, 2026, expanding the board to thirteen members, and named him to its Operations & Innovation and Audit Committees. Boehnlein, previously vice president and chief financial officer of Stryker Corporation from 2016 to 2025 and afterward an advisor to Stryker's CEO, was granted an initial equity award of restricted stock units valued at $500,000; CEO Jake Leach said he was selected for his MedTech and financial experience as Dexcom executes its long-range plan.
Key points
- The board appointed Boehnlein for a term expiring at Dexcom's 2027 annual stockholders meeting and determined he qualifies as an independent director under Nasdaq listing standards.
- The initial RSU grant of $500,000 vests annually over three years, and he is eligible for the annual non-employee director grant of $347,500 in RSUs around the 2027 annual meeting.
- Boehnlein served as CFO and vice president of Stryker's MedSurg and Neurotechnology Group from 2011 to 2015 and as CFO of its Endoscopy Division from 2003 to 2010, and was a partner at Arthur Andersen LLP.
- He currently sits on the boards of Inogen, where he chairs the audit committee, Agilent Technologies, and Sutter Health.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
- 7.01Regulation FD Disclosure
- 9.01Financial Statements and Exhibits
From the filing
ITEM 5.02. DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS. On September 10, 2026, the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”), pursuant to the Amended and Restated Bylaws of the Company, increased the size of the Board to thirteen directors and appointed Glenn S. Boehnlein as a director, effective immediately. Mr. Boehnlein will hold office for a term expiring at the 2027 annual meeting of Dexcom’s stockholders (the “2027 Annual Meeting”). The Board also appointed Mr. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.